Earlier today in our third quarter results conference call, we announced that our aggregate partner company revenue increased 73 percent in Q3, and that for…
Posted by
On the eve of the International Conference on Alzheimer’s Disease (ICAD), Bloomberg Businessweek’s Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard…
Posted by
Avid Radiopharmaceuticals was featured on the front page of The New York Times today. The article, “Promise Seen for Detection of Alzheimer’s,” by Gina Kolata (@ginakolata), highlights…
Posted by
On the heels of the BIO International Convention, I came across this piece by FierceBiotech’s Maureen Martino highlighting a panel of biotech VCs who made…
Posted by
Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…
Posted by
I frequently attribute Safeguard Scientifics’ success to our disciplined strategy built on five strategic themes, which we refer to as M2C3. We leverage these themes…
Posted by
In our report for the period ended Dec. 31, 2009 that was released this morning, we updated investors on the significant progress achieved by Safeguard…
Posted by
Safeguard Scientifics’ partner company Avid Radiopharmaceuticals was invited to present its technology and growth strategy at the prestigious J.P. Morgan 28th Annual Healthcare Conference in…
Posted by
Bruce Bigelow of Xconomy San Diego highlights Advanced BioHealing’s (ABH) commercial success with Dermagraft in his article. Bigelow details the success of Dermagraft and ABH’s…
Posted by
